EA200101240A1 - Использование мелатонина в медицине - Google Patents

Использование мелатонина в медицине

Info

Publication number
EA200101240A1
EA200101240A1 EA200101240A EA200101240A EA200101240A1 EA 200101240 A1 EA200101240 A1 EA 200101240A1 EA 200101240 A EA200101240 A EA 200101240A EA 200101240 A EA200101240 A EA 200101240A EA 200101240 A1 EA200101240 A1 EA 200101240A1
Authority
EA
Eurasian Patent Office
Prior art keywords
melatonin
symptoms
patient
tardive dyskinesia
medicine
Prior art date
Application number
EA200101240A
Other languages
English (en)
Other versions
EA004057B1 (ru
Inventor
Нава Зисапел
Моше Лаудон
Original Assignee
Неурим Фармасьютикалс (1991) Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Неурим Фармасьютикалс (1991) Лтд. filed Critical Неурим Фармасьютикалс (1991) Лтд.
Publication of EA200101240A1 publication Critical patent/EA200101240A1/ru
Publication of EA004057B1 publication Critical patent/EA004057B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4515—Non condensed piperidines, e.g. piperocaine having a butyrophenone group in position 1, e.g. haloperidol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение относится к способу профилактики или лечения симптомов поздней дискинезии у больного путем введения ему мелатонина в эффективном количестве; а также к фармацевтическому составу, включающему, по крайней мере, одно нейролептическое соединение в количестве, эффективном для проявления нейролептического эффекта у нуждающегося в соответствующем воздействии больного, и мелатонин в количестве, эффективном для облегчения проявления симптомов поздней дискинезии, или предотвращения развития таких симптомов.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200101240A 1999-05-27 2000-05-24 Использование мелатонина в медицине EA004057B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL13017199A IL130171A (en) 1999-05-27 1999-05-27 Melatonin for use in preventing and treating tardive dyskinesia, pharmaceutical preparations containing it and its use in the manufacture of medicines
PCT/IL2000/000296 WO2000072843A1 (en) 1999-05-27 2000-05-24 Therapeutic use of melatonin

Publications (2)

Publication Number Publication Date
EA200101240A1 true EA200101240A1 (ru) 2002-06-27
EA004057B1 EA004057B1 (ru) 2003-12-25

Family

ID=11072852

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200101240A EA004057B1 (ru) 1999-05-27 2000-05-24 Использование мелатонина в медицине

Country Status (30)

Country Link
US (1) US6566389B1 (ru)
EP (1) EP1183024A4 (ru)
JP (1) JP2003500446A (ru)
KR (1) KR20020015329A (ru)
CN (1) CN1176652C (ru)
AR (1) AR036321A1 (ru)
AU (1) AU775520B2 (ru)
BG (1) BG106234A (ru)
BR (1) BR0017329A (ru)
CA (1) CA2374129A1 (ru)
CZ (1) CZ20014190A3 (ru)
EA (1) EA004057B1 (ru)
EE (1) EE200100623A (ru)
HK (2) HK1046089A1 (ru)
HU (1) HUP0201405A3 (ru)
IL (1) IL130171A (ru)
IS (1) IS6172A (ru)
MX (1) MXPA01012040A (ru)
NO (1) NO319421B1 (ru)
NZ (1) NZ515866A (ru)
PE (1) PE20010129A1 (ru)
PL (1) PL351885A1 (ru)
SK (1) SK16402001A3 (ru)
TN (1) TNSN00117A1 (ru)
TR (1) TR200103418T2 (ru)
TW (1) TWI236906B (ru)
UA (1) UA71968C2 (ru)
UY (1) UY26171A1 (ru)
WO (1) WO2000072843A1 (ru)
ZA (1) ZA200110436B (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ527142A (en) * 2003-07-23 2006-03-31 Douglas Pharmaceuticals Ltd A stable suspension formulation
EP1715742A4 (en) * 2004-02-20 2009-06-17 Lifescape Biosciences Inc COMPOSITIONS AND METHODS FOR SLEEPING
CN1299680C (zh) * 2005-08-29 2007-02-14 陈彦方 一种治疗失眠的黑白制剂
US7494674B2 (en) 2006-09-22 2009-02-24 Lapointe Andrew T Nutraceutical with tart cherries and method of treatment therewith
WO2008116004A2 (en) 2007-03-19 2008-09-25 Vita Sciences, Llc Transdermal patch and method for delivery of vitamin b12
WO2008128166A1 (en) * 2007-04-13 2008-10-23 Concert Pharmaceuticals Inc. Deuterated derivatives of 4-(6-fluoro-1, 2-benzisoxazol-3-yl) piperidine compounds
US20100256197A1 (en) * 2009-04-02 2010-10-07 Silver Eagle Labs Nv, Llc Nicotine Dissolving Film With Or Without Menthol
US20100256215A1 (en) * 2009-04-02 2010-10-07 Silver Eagle Labs Nv, Llc Menthol-Melatonin Dissolving Film
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
US8691275B2 (en) 2011-01-28 2014-04-08 Zx Pharma, Llc Controlled-release melatonin compositions and related methods
FR3000896B1 (fr) 2013-01-14 2016-08-26 Philippe Perovitch Forme galenique pour l'administration de principe(s) actif(s) permettant l'induction acceleree du sommeil et/ou le traitement des troubles du sommeil
US11071739B1 (en) 2020-09-29 2021-07-27 Genus Lifesciences Inc. Oral liquid compositions including chlorpromazine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5691324A (en) * 1994-01-14 1997-11-25 Sandyk; Reuven Methods useful for the treatment of neurological and mental disorders related to deficient serotonin neurotransmission and impaired pineal melatonin functions
US6469044B1 (en) * 1995-02-01 2002-10-22 Neurim Pharmaceuticals (1991) Ltd. Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies
AUPO274596A0 (en) * 1996-10-04 1996-10-31 Armstrong, Stuart Maxwell Method for the treatment of neurological or neuropsychiatric disorders
AUPO588297A0 (en) * 1997-03-26 1997-04-24 Luminis Pty Limited Mediation in melatonin production

Also Published As

Publication number Publication date
CZ20014190A3 (cs) 2002-05-15
HK1047048B (zh) 2005-05-27
JP2003500446A (ja) 2003-01-07
SK16402001A3 (sk) 2002-04-04
NO20015738L (no) 2002-01-25
PE20010129A1 (es) 2001-04-27
EE200100623A (et) 2003-02-17
TWI236906B (en) 2005-08-01
TNSN00117A1 (fr) 2005-11-10
IL130171A0 (en) 2000-06-01
NZ515866A (en) 2003-05-30
WO2000072843A1 (en) 2000-12-07
AR036321A1 (es) 2004-09-01
KR20020015329A (ko) 2002-02-27
PL351885A1 (en) 2003-06-30
AU4775600A (en) 2000-12-18
NO20015738D0 (no) 2001-11-26
HUP0201405A2 (en) 2002-08-28
EA004057B1 (ru) 2003-12-25
TR200103418T2 (tr) 2004-12-21
MXPA01012040A (es) 2003-09-04
CA2374129A1 (en) 2000-12-07
ZA200110436B (en) 2004-03-31
IL130171A (en) 2004-06-01
BG106234A (bg) 2002-08-30
HK1046089A1 (zh) 2002-12-27
UA71968C2 (en) 2005-01-17
BR0017329A (pt) 2003-07-29
CN1352556A (zh) 2002-06-05
CN1176652C (zh) 2004-11-24
HK1047048A1 (en) 2003-02-07
NO319421B1 (no) 2005-08-08
UY26171A1 (es) 2000-12-29
IS6172A (is) 2001-11-22
EP1183024A1 (en) 2002-03-06
HUP0201405A3 (en) 2003-11-28
AU775520B2 (en) 2004-08-05
US6566389B1 (en) 2003-05-20
EP1183024A4 (en) 2007-02-28

Similar Documents

Publication Publication Date Title
EA200200105A1 (ru) СОЕДИНЕНИЯ, МОДУЛИРУЮЩИЕ АКТИВНОСТЬ PPARγ;
ATE360630T1 (de) Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors
CY1107467T1 (el) Χρηση οξεογονων υδρογονοτροφων στελεχων για την προληψη ή την αγωγη πεπτικων διαταραχων
RU94029662A (ru) Фосфонооксиметиловые эфиры производных таксана, фармацевтическая композиция, способы лечения
ATE339406T1 (de) Chinazoline verbindungen als heilmittel
ATE303162T1 (de) Natrium kanalblocker zusammensetzungen und deren verwendung
EA200201271A1 (ru) Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1
EA200100572A1 (ru) Способ применения ингибитора циклооксигеназы-2 и одного или нескольких противоопухолевых лекарственных средств в качестве комбинированного способа лечебного воздействия при лечении неоплазии
ATE360631T1 (de) Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors
EA200300776A1 (ru) Производные фенэтаноламина для лечения респираторных заболеваний
EA200101005A1 (ru) Высокоэффективные композиции, содержащие дигидроэрготамин
BR9502707A (pt) Composto composição farmacêutica e método para o tratamento de uma afecção
CY1111153T1 (el) Μορφη οσμοτικης δοσολογιας παρατεταμενης απελευθερωσης
PT1319007E (pt) Compostos de succinimida heterociclicos fundidos e seus analogos enquanto moduladores da funcao dos receptores hormonais nucleares
EA200401471A1 (ru) Применение ингибиторов сетр и возможных ингибиторов hmg coa и/или антигипертензивных агентов
EA200101240A1 (ru) Использование мелатонина в медицине
EA200500782A1 (ru) Лечение геморрагического шока
EA200000911A1 (ru) Новые кристаллические формы антивирусного соединения бензимидазола
ATE243196T1 (de) Piperidine und pyrrolidine
BR9707247A (pt) Diidrobenzofurano e compostos relacionados úteis como agentes antiinflamatórios
EA200500348A1 (ru) N-арилпиперидинзамещенные бифенилкарбоксамиды в качестве ингибиторов секреции аполипопротеина b
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
EA200970127A1 (ru) Модулятор рецепторов глюкокортикостероидов и способы его применения
EA200200502A1 (ru) Способ введения ингибитора фосфодиэстеразы 4
EA200100540A1 (ru) Фармацевтическая композиция с модифицированным высвобождением сенсибилизатора к инсулину

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU